冠心病患者血小板聚集功能及噻氯匹啶作用的观察

目的:探讨冠心病患者血小板聚集功能以及噻氯匹啶对此过程的抑制作用。方法:应用比浊法测量冠心病患者服药前后,由二磷酸腺苷(ADP)、肾上腺素(EPI)、胶原(Coll)和磷酯花生四烯酸(ACA)诱导的血小板聚集功能。结果:患病组ADP、EPI诱导的最大血小板聚集率(0.78±0.23,0.86±0.25)明显高于对照组(0.65±0.19,P＜0.05;0.73±0.21,P＜0.05),且被噻氯匹啶明显抑制(0.68±0.18,P＜0.05;0.75±0.20,P＜0.05)。而两组间Coll和ACA诱导的最大血小板聚集率无明显差异,且患病组治疗前后无明显差异。结论:冠心病患者血小板聚集功能明显增强,噻氯匹啶可明显抑制这一过程。

Study of platelet aggregations in patients with coronary heart disease and the effect of ticlopidine treatment

AIM: To investigate the platelet aggregations in patients with coronary heart disease(CHD) and the effect of ticlopidine treatment. METHODS: Platelet aggregations induced by adenosine diphosphate(ADP), epinephrine(EPI), collagen(Coll), arachidonic acid(ACA) in CHD group before and after ticlopidine treatment were measured by turbidity assay. RESULTS: Maximum ratios of platelet aggregations (max%) induced by ADP, EPI in CHD group (0.78±0.23, 0.86±0.25) were significantly higher than that of control group (0.65±0.19, 0.73±0.21, P＜0.05). After the treatment with ticlopidine, they were lowered obviously (0.68±0.18, P＜0.05;0.75±0.20, P＜0.05). There were no difference in max% induced by Coll and ACA between two groups and there were no significantly changes of max% induced by Coll and ACA by ticlopidine in CHD group. CONCLUSION: The platelet aggregations were increased in patients with coronary heart disease and could be inhibited by ticlopidine.